ArticleEuropean journal of medical research2025
Prevalence and associated factors of psychotic symptoms in young first-episode, drug-naïve major depressive disorder patients with abnormal lipid metabolism.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The correlations between psychotic symptoms and childhood maltreatment as well as sex differences in adolescents with major depressive disorder.European archives of psychiatry and clinical neuroscience · 2026Article
- SIRI, SII, and PNI in psychiatric patients with positive urinary drug metabolites: association with immune and nutritional biomarkers.BMC psychiatry · 2026Article
- Lipid metabolism dysregulation in late-life depression: peripheral metabolic disturbance, central lipid alterations, and dietary modulation.Frontiers in nutrition · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundComorbidity of major depressive disorder (MDD) and abnormal lipid metabolism (ALM) is common. Psychotic major depression (PMD) is a severe subtype of MDD. However, the occurrence of psychotic symptoms in MDD patients with ALM has not been thoroughly investigated. This study aimed to explore the risk factors for psychotic symptoms in MDD patients with ALM.
methodsA total of 1289 first-episode, drug-naïve (FEDN) MDD patients aged 18-45 years were recruited. Sociodemographic data and various clinical parameters, including lipid profiles, thyroid function tests, and thyroid antibodies, were measured. Patients were evaluated using the Hamilton Rating Scale for Depression (HAMD), Hamilton Anxiety Rating Scale (HAMA), and the positive subscale of the Positive and Negative Syndrome Scale (PANSS).
resultsIn the FEDN MDD sample, the prevalence of ALM was 81.12% (1047/1289). Among MDD patients with ALM, levels of total cholesterol (TC), HAMA, HAMD, suicide attempts, TSH, TgAb, TPOAb, fasting glucose, and blood pressure were significantly higher in the PMD group than in the NPMD group. Binary logistic regression indicated that HAMD scores (OR = 1.187 [1.045, 1.349], P = 0.0085), HAMA scores (OR = 1.699 [1.510, 1.912], P < 0.0001), and TSH levels (OR = 1.116 [1.001, 1.234], P = 0.0472) were independent risk factors for psychotic symptoms in MDD patients with ALM.
conclusionOur study identified a high prevalence of psychotic symptoms in young MDD patients with ALM. Key predictors, including HAMD, HAMA, and TSH, demonstrated strong predictive accuracy. These findings highlight the potential of these factors for early identification of psychotic symptoms in this patient population. Future research is needed to validate these results and explore the underlying mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.